Thursday, November 4, 2010

Alnylam Green Shoots After Corporate Restructuring

The latest quarter must have been the best quarterly performance by Alnylam in the last 3 years. After going through a rough patch that culminated in Novartis not adopting a widely expected $100M platform license with the attendant lay-off of a third of its staff, the results and also tone of the conference call struck me as if the company had re-discovered its old enthusiasm for RNAi Therapeutics drug development and is intensely focused on creating value by providing additional clinical proof-of-concept data over the coming months.

There is reason to be cautiously optimistic about the upcoming clinical data. For one, dose escalation for the liver cancer candidate ALN-VSP02 seems to have progressed beyond the magic 1mg/kg mark and is still ongoing! First generation or not, the fact that patients have now received and tolerated this kind of dosage, and on a repeat basis, is major de-risking for all of Alnylam’s, but also Tekmira’s pipeline candidates which involve LNP delivery (almost all of them). Similarly encouraging, ALN-TTR01 dosing is also ongoing and with 3 centers in Europe recruiting now, results may not be that far off (28 patients anticipated in this phase I study).

Although the first generation LNPs appear to be well tolerated, Alnylam seems to be even more excited about a potential quantum leap in LNP delivery: LNPs containing the next-generation MC3 lipid which not only silence in the unprecedented single micro-gram per kg range for gene targets in the liver, but also appear to be very well tolerated in animals. The MC3 lipids are derived from the DLin-KC2-DMA ionizable lipids developed by Tekmira, results from which were published earlier this year in Nature Biotech.

Besides the science, financials seem to be in better-than-expected shape, and I believe is what underlies today’s jump in share price (you can assume that the stock market wouldn't pay much attention to MC3). With over $370M cash/equivalents on the balance sheet, Alnylam is poised to close the year with well over the previously guided $325M cash/equivalents. Having slashed the work force, albeit probably at considerable personal cost, thus buys the company strategically valuable breathing room. In addition, there were a number of positive one-offs this quarter, including $2M for the successful award of 8 federal grants, a Quark milestone, and increased activities related to Novartis finalizing its 31 target picks. And with Novartis' relationship with Alnylam settled now, it should become easier to talk to other companies about partnerships and further add to the strong financial position.

Alnylam and Medtronic also stand to receive very significant funding from the Huntington’s Disease Foundation (CHDI), likely totaling over $10M, some of which has already been earned (agreement is retro-active). Somewhat dampening the excitement around that program was news that ALN-HTT is now a 2012 goal for entering the clinic, while LNP-delivered ALN-TTR02 and PCSK9 (both probably MC3) are poised to be the Company’s 2011 new clinical candidates.

An interesting tidbit on PCSK9 is that, faced with numerous competition from mainly monoclonal antibody candidates against the same target, some of which have already entered the clinic, it appears to be now Alnylam’s strategy to emphasize the fact that with RNAi you down-regulate both intra- and extracellular PCSK9 levels, which therefore is closest to recapitulating human genetics which has been driving the adoption of PCSK9 as a drug target for hypercholesterolemia in the first place. A good argument indeed.

Overall, my most important take-home was that this seems to be a re-energized company, and with some of the right clinical news, there may soon be a second honeymoon between Alnylam and its shareholders (of whom I’m btw not one of…yet).

5 comments:

Anonymous said...

Dirk, inthought alny was developing their own delivery system, so are they more excited by tekmira next generation lipid nanos?

Sam

Dirk Haussecker said...

The relationship seems complicated. What you may be referring to is the old cationic 'lipidoid' (MIT) vs ionizable SNALP (Tekmira) controversy/confusion. Today, it seems that ionizable lipids are preferable for most indications and in that sense Alnylam values 'Tekmira's' lipids more highly. With the UBC/AlCana relationship, all this however becomes slightly more complicated.

In the case of MC3 it appears that the DLin-KC2-DMA precursor was developed at Tekmira, but by people now at AlCana and therefore closer to Alnylam. This group also appears to have developed MC3. Tekmira has access to those lipids.

The way I see it is that Tekmira clearly built LNP/SNALP technology into the leading systemic RNAi delivery platform, and Alnylam (and Sirna/Merck) has spotted that potential early on and has started to heavily invest in the technology. Because of Tekmira's access to Alnylam's LNP inventions (including 'lipidoids'), this also benefits in a way Tekmira, e.g. if Tekmira agrees with Alnylam's assessment of MC3 lipids and uses it in the ApoB-2 program.

Anonymous said...

Dirk,
Although ALNY/ Medtronic jiont project focusing on HTT win the CHDI funding. I still think Merk's ddRNAi still got the chance to win back the HTT by filing IND ahead of ALNY, Then maybe CHDI will put the money back to Merk, CHDI has been a money donor for many years, ISIS accepts its funding but no result coming out.

Anonymous said...

"The MC3 lipids are derived from the DLin-KC2-DMA ionizable lipids developed by Tekmira"

Who owns the IP, licensing rights, and who has the technical know how for MC3?

It seems MC3 is being developed by Tekmira, University of British Columbia, Alcana (UBC?), and Alnylam.

However, I can't figure out the commerical relationship between all these parties.

Can anyone help?

Can anyone shed some light on the

Dirk Haussecker said...

It's likely that Alnylam funds the studies and that Tekmira gets free and non-exclusive access to the newly discovered lipids. Somewhat unfortunate for Tekmira is that the recently issued DLin-DMA claims were quite narrow and do not cover the many DLin-DMA-derived lipids that now turn out to have therapeutic potential, including MC3- at least that's how I read those patents.

By Dirk Haussecker. All rights reserved.

Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.